Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.39 |
| ▸ | PGK1 | P00558 | 5/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19675875 | 0.85 | STK17A (0.43) | NUDT1LMNAALDH1A1L3MBTL1STK17A | |
| SCHEMBL1935303 | 0.82 | STK17B (0.47) | LMNAALDH1A1L3MBTL1STK17APGK1 | |
| SCHEMBL13648989 | 0.80 | NUDT1 (0.38) | NUDT1ALDH1A1L3MBTL1STK17APGK1 | |
| SCHEMBL14112779 | 0.80 | KDM4E (0.45) | NUDT1ALDH1A1L3MBTL1STK17ASTK17B | |
| SCHEMBL25584087 | 0.80 | KMT2A (0.44) | LMNAL3MBTL1STK17ASTK17BKMT2A | |
| SCHEMBL3646724 | 0.79 | LMNA (0.39) | LMNAALDH1A1L3MBTL1STK17APGK1 | |
| SCHEMBL1427747 | 0.79 | ALDH1A1 (0.63) | LMNAALDH1A1L3MBTL1STK17APGK1 | |
| SCHEMBL13897499 | 0.79 | MEN1 (0.52) | LMNAALDH1A1L3MBTL1STK17APGK1 | |
| SCHEMBL1801013 | 0.79 | LMNA (0.39) | LMNAALDH1A1L3MBTL1PGK1KMT2A | |
| SCHEMBL6457831 | 0.78 | XDH (0.42) | NUDT1ALDH1A1L3MBTL1STK17AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-11078165-B2 | Compounds for treating tuberculosis | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2021-08-03 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2020-07-23 | — | — | US | disclosed |
| WO-2018151681-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2018-08-23 | — | — | WO | disclosed |
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-7820648-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-1966207-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072158-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | NUDT1 36/4885LMNA 2814/4885ALDH1A1 714/4885 |
| US-11078165-B2 | Compounds for treating tuberculosis | ATP5ME, ATP5MG, ATP5F1D | NUDT1 187/4885LMNA 3226/4885ALDH1A1 823/4885 |
| US-20200231550-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | ATP5ME, ATP5MG, ATP5F1D | NUDT1 187/4885LMNA 3226/4885ALDH1A1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.